credentis ag Release: Clinical Trial Proves Superiority Of Guided Enamel Regeneration With CURODONT REPAIR
In their newly published manuscript titled “Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel” the paediatric dentistry group of Prof. Christian Splieth from the University of Greifswald presented results from a randomised clinical trial proving that Guided Enamel Regeneration Therapy of early caries with CURODONT™ REPAIR and fluoride is highly superior to the present gold-standard of fluoride alone.
The pivotal trial published in the prestigious Journal of Dental Research showed superior results for the CURODONT™ REPAIR group in all clinical outcome parameters – including 80% vs 34% inactivated caries lesions, four-times the number of regressed caries lesions, and a 15-times higher decrease in the caries diagnostic signal.
The researchers conclude their milestone paper with the statement that “the data demonstrated that biomimetic mineralization facilitated by P11-4 [CURODONT™ REPAIR] in combination with fluoride is a simple, safe, and effective noninvasive treatment for early carious lesions and is superior to the present clinical gold standard of fluoride treatment alone”.
Link to article:
Alkilzy M, Tarabaih A,, Santamaria RM, Splieth CH, Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel. J Dent Res https://doi.org/10.1177/0022034517730531
CURODONT™ REPAIR is marketed in Switzerland under the brand name REGENAMEL®
About credentis ag
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds and CTI in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
The pivotal trial published in the prestigious Journal of Dental Research showed superior results for the CURODONT™ REPAIR group in all clinical outcome parameters – including 80% vs 34% inactivated caries lesions, four-times the number of regressed caries lesions, and a 15-times higher decrease in the caries diagnostic signal.
The researchers conclude their milestone paper with the statement that “the data demonstrated that biomimetic mineralization facilitated by P11-4 [CURODONT™ REPAIR] in combination with fluoride is a simple, safe, and effective noninvasive treatment for early carious lesions and is superior to the present clinical gold standard of fluoride treatment alone”.
Link to article:
Alkilzy M, Tarabaih A,, Santamaria RM, Splieth CH, Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel. J Dent Res https://doi.org/10.1177/0022034517730531
CURODONT™ REPAIR is marketed in Switzerland under the brand name REGENAMEL®
About credentis ag
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds and CTI in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.